Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Cell Density Monitoring (VCD, OD600) in Bioreactor Operations – V 2.0

Posted on By


Biosimilars: SOP for Cell Density Monitoring (VCD, OD600) in Bioreactor Operations – V 2.0


Standard Operating Procedure for Cell Density Monitoring (VCD, OD600) in Bioreactor Operations for Biosimilars

Department Biosimilars
SOP No. SOP/BS/080/2025
Supersedes SOP/BS/080/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the standardized procedure for monitoring cell density in bioreactor operations using Viable Cell Density (VCD) via hemocytometer/automated counter and Optical Density (OD600) using a spectrophotometer during biosimilar production.

2. Scope

This SOP applies to upstream bioprocessing units involved in biosimilar production utilizing mammalian or microbial systems requiring real-time cell density monitoring.

3. Responsibilities

  • Bioprocess Technician: Collect and measure cell density at defined intervals and maintain logs.
  • QC Analyst: Calibrate instruments and validate measurement accuracy.
  • QA Personnel: Review data logs and ensure SOP compliance.

4. Accountability

The Upstream Processing Manager is accountable for accurate implementation and compliance with cell density monitoring protocols.

5. Procedure

5.1 Sampling for Cell Density

  1. Collect ~5 mL of culture fluid aseptically using SOP/BS/078/2025.
  2. Transfer to labeled tubes and proceed with VCD or OD600 measurement immediately.

5.2 VCD Measurement Using Hemocytometer or Cell Counter

  1. Mix 100 µL of sample with 100 µL of 0.4% trypan blue solution.
  2. Load 10 µL into hemocytometer and observe under microscope (manual method) or use automatic cell counter.
  3. Count viable (unstained) and non-viable (blue) cells in 4 corner squares.
  4. Calculate VCD using:
    • VCD (cells/mL) = Average viable count × Dilution Factor × 104
  5. Log data in Annexure-1.

5.3 OD600 Measurement (Primarily for Microbial Culture)

  1. Zero the spectrophotometer with fresh culture medium as blank at 600 nm.
  2. Measure absorbance of culture sample diluted to fall within 0.1–1.0 OD range.
  3. Use conversion factor for approximate CFU/mL if required.
  4. Record OD600 readings and time in Annexure-2.

5.4 Instrument Calibration

  1. Calibrate cell counter monthly using standard beads or reference slides.
  2. Verify OD600 accuracy quarterly using traceable reference standards.

5.5 Documentation

  1. Enter data in Bioreactor Monitoring Log and VCD/OD Log (Annexures 1 & 2).
  2. Review trends to monitor growth rate and trigger feeding or harvest decisions.

6. Abbreviations

  • VCD: Viable Cell Density
  • OD600: Optical Density at 600 nm
  • CFU: Colony Forming Units

7. Documents

  1. VCD Measurement Log – Annexure-1
  2. OD600 Monitoring Sheet – Annexure-2

8. References

  • USP <1046> – Cell Viability Assays
  • ICH Q9 – Quality Risk Management

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: VCD Measurement Log

Date Time Batch No. VCD (cells/mL) Viability (%) Operator
04/05/2025 10:00 BS-080-B01 6.2 × 106 94% Rajesh Kumar

Annexure-2: OD600 Monitoring Sheet

Date Time Batch No. OD600 Dilution Factor Operator
04/05/2025 10:15 BS-080-M01 0.78 10x Sunita Reddy

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Added automated counter method and OD600 calibration Technology Upgrade
See also  Biosimilars: SOP for Storage of Purified Bulk Product - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Analytical Method Development: HPLC Sample Preparation Strategy – V 2.0
Next Post: Aerosol: SOP for Updating Validation Master Plans for Aerosol Manufacturing – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version